Vertex Pharmaceuticals (BSP:VRTX34) Short-Term Capital Lease Obligation : R$0 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Vertex Pharmaceuticals Short-Term Capital Lease Obligation?

Vertex Pharmaceuticals's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was R$0 Mil.

Vertex Pharmaceuticals's quarterly Short-Term Capital Lease Obligation increased from Sep. 2023 (R$0 Mil) to Dec. 2023 (R$410 Mil) but then declined from Dec. 2023 (R$410 Mil) to Mar. 2024 (R$0 Mil).

Vertex Pharmaceuticals's annual Short-Term Capital Lease Obligation increased from Dec. 2021 (R$454 Mil) to Dec. 2022 (R$469 Mil) but then declined from Dec. 2022 (R$469 Mil) to Dec. 2023 (R$410 Mil).

Vertex Pharmaceuticals Short-Term Capital Lease Obligation Historical Data

The historical data trend for Vertex Pharmaceuticals's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Short-Term Capital Lease Obligation Chart

Vertex Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

159.23

218.14

453.52

468.94

410.11

Vertex Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	-	-	410.11	-

Vertex Pharmaceuticals Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Vertex Pharmaceuticals Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Vertex Pharmaceuticals (BSP:VRTX34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (BSP:VRTX34) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

VRTX:USA VRTX:Mexico 1VRTX:Italy VX1d:UK VX1:Germany VRTX:Austria

Address

50 Northern Avenue, Boston, MA, USA, 02210

Website

https://www.vrtx.com

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Vertex Pharmaceuticals (BSP:VRTX34) Headlines

No Headlines